Risk of imminent fracture following a previous fracture in a Swedish database study

por Banefelt, J., Åkesson, K.E., Spångéus, A., Ljunggren, O., Karlsson, L., Ström, O., Ortsäter, G., Libanati, C., Toth, E.
Publicado 2019

A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis

por Söreskog, E., Borgström, F., Lindberg, I., Ström, O., Willems, D., Libanati, C., Kanis, J. A., Stollenwerk, B., Charokopou, M.
Publicado 2021

Comorbidity indices for clinical trials: adaptation of two existing indices for use with the FREEDOM trial in women with postmenopausal osteoporosis

por Silverman, S. L., Wang, A., Cheng, L., Yang, Y., Libanati, C., Geller, M., Grauer, A., Nevitt, M., Revicki, D., Viswanathan, H. N.
Publicado 2015

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab

por Kendler, D.L., Bone, H.G., Massari, F., Gielen, E., Palacios, S., Maddox, J., Yan, C., Yue, S., Dinavahi, R.V., Libanati, C., Grauer, A.
Publicado 2019

Secular trends in the initiation of therapy in secondary fracture prevention in Europe: a multi-national cohort study including data from Denmark, Catalonia, and the United Kingdom...

por Skjødt, M. K., Khalid, S., Ernst, M., Rubin, K. H., Martinez-Laguna, D., Delmestri, A., Javaid, M. K., Cooper, C., Libanati, C., Toth, E., Abrahamsen, B., Prieto-Alhambra, D.
Publicado 2020

The treatment gap after major osteoporotic fractures in Denmark 2005-2014: a combined analysis including both prescription-based and hospital-administered anti-osteoporosis medicat...

por Skjødt, M. K., Ernst, M. T., Khalid, S., Libanati, C., Cooper, C., Delmestri, A., Rubin, K. H., Javaid, M. K., Martinez-Laguna, D., Toth, E., Prieto-Alhambra, D., Abrahamsen, B.
Publicado 2021

Relationship Between Bone Mineral Density T‐Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment

por Ferrari, S, Libanati, C, Lin, Celia Jow Fang, Brown, JP, Cosman, F, Czerwiński, E, de Gregόrio, LH, Malouf‐Sierra, J, Reginster, J‐Y, Wang, A, Wagman, RB, Lewiecki, EM
Publicado 2019

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

por Ferrari, S., Adachi, J. D., Lippuner, K., Zapalowski, C., Miller, P. D., Reginster, J.-Y., Törring, O., Kendler, D. L., Daizadeh, N. S., Wang, A., O’Malley, C. D., Wagman, R. B., Libanati, C., Lewiecki, E. M.
Publicado 2015

Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group

por Bilezikian, J.P., Lin, C.J.F., Brown, J.P., Wang, A.T., Yin, X., Ebeling, P.R., Fahrleitner-Pammer, A., Franek, E., Gilchrist, N., Miller, P.D., Simon, J.A., Valter, I., Zerbini, C.A.F., Libanati, C., Chines, A.
Publicado 2019

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

por Papapoulos, S., Lippuner, K., Roux, C., Lin, C. J. F., Kendler, D. L., Lewiecki, E. M., Brandi, M. L., Czerwiński, E., Franek, E., Lakatos, P., Mautalen, C., Minisola, S., Reginster, J. Y., Jensen, S., Daizadeh, N. S., Wang, A., Gavin, M., Libanati, C., Wagman, R. B., Bone, H. G.
Publicado 2015